title: Epitope characterization of pre-existing and developing antibodies to an aglycosylated monoclonal antibody therapeutic of G1m17,1 allotype.
abstract: Allotypes of IgG1 molecules can influence the immunogenicity of therapeutic monoclonal antibodies and may account for the presence of some pre-existing antibodies. An electrochemiluminescent (ECL) bridging immunoassay was used to characterize the binding epitopes of anti-therapeutic antibodies (ATAs) in a Phase 1 single ascending dose clinical trial of a therapeutic aglycosylated IgG1monoclonal antibody (mAb). There was no evidence for ATAs specific for a possible neo-epitope created due to the lack of glycosylation. ATAs that developed post-treatment were specific for the F(ab')2, whereas, pre-existing ATAs were specific to the Fc region. Further characterization of the pre-existing ATAs identified the specific epitope to be the G1m1 allotype determinant in the Fc of the therapeutic. A novel competitive bridging assay was developed to verify that serum IgG1 from subjects with pre-existing anti-G1m1 antibodies was homozygous for the antithetical allotype (G1m3). The endogenous G1m allotype of all subjects was assessed and correlation to ATA incidence and adverse events was evaluated. Interestingly, the pre-existing anti-allotype antibody in subjects persisted but was not augmented after dosing, indicating the lack of a secondary immune response to this epitope. These studies indicate the relationship of the therapeutic allotype and the corresponding allotype of subjects is an important component to further understand the impact of immunogenicity on the safety and efficacy of therapeutic antibodies.
authors.affiliation: Clinical Immunology, Amgen, Thousand Oaks, CA 91320‐1799, United States. suzannat@amgen.com
authors.forename: Suzanna M
authors.initials: SM
authors.lastname: Tatarewicz
authors.forename: Gloria
authors.initials: G
authors.lastname: Juan
authors.forename: Steven J
authors.initials: SJ
authors.lastname: Swanson
authors.forename: Michael S
authors.initials: MS
authors.lastname: Moxness
mesh_terms: D000906:Antibodies / Q000737:chemistry / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D004311:Double-Blind Method; D000939:Epitopes / Q000737:chemistry / Q000276:immunology*; D006031:Glycosylation; D006801:Humans; D007126:Immunoglobulin Allotypes / Q000276:immunology*; D007074:Immunoglobulin G / Q000276:immunology / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
chemical_list: D000906:Antibodies; D000911:Antibodies, Monoclonal; D000939:Epitopes; D007126:Immunoglobulin Allotypes; D007074:Immunoglobulin G